Chardan Capital raises Taysha Gene PT to $12, maintains Buy rating.

Wednesday, Nov 5, 2025 7:49 am ET1min read
TSHA--

Chardan Capital raises Taysha Gene PT to $12, maintains Buy rating.

Chardan Capital raises Taysha Gene PT to $12, maintains Buy rating.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet